Table 1.

Major CRT trials with outcomes

Trial	Total No. of Subjects (% Female)	Inclusion Criteria	Randomization	HR for Events (95% CI)
COMPANION16	1520 (33)	LVEF ≤35%, NYHA class III–IV, QRSd ≥120 ms	OMT vs OMT + CRT‐D	HR for death: men, 0.63 (0.4‐0.9); women, 0.58 (0.25‐1.13)
CARE‐HF14	813 (27)	LVEF ≤35%, NYHA class III–IV, QRSd ≥120 ms, LVEDD ≥30 mm	OMT vs OMT + CRT	HR for death or cardiac hospitalization: men, 0.62 (0.49‐0.79); women, 0.64 (0.42‐0.97)
MADIT‐CRT17	1820 (25)	LVEF ≤30%, NYHA class I–II, QRSd ≥130 ms	ICD vs CRT‐D	HR for HF event or death: men, 0.76 (0.59‐0.97); women, 0.37 (0.22‐0.61)
RAFT15	1798 (17)	LVEF ≤30%, NYHA class II–III, QRSd ≥120 ms	ICD vs CRT‐D	HR death or HF admission: men, 0.82 (0.7‐0.95); women, 0.52 (0.35‐0.85). Difference between men and women is not significant (P = 0.09).
MIRACLE13	453 (32)	LVEF ≤35%, NYHA class III–IV, QRSd ≥130 ms	Placebo vs CRT	Women, but not men, with CRT experienced longer times to first HF hospitalization or death (HR in women: 0.157).

Abbreviations: CARE‐HF, Cardiac Resynchronization–Heart Failure; CI, confidence interval; COMPANION, Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure; CRT, cardiac resynchronization therapy; CRT‐D, cardiac resynchronization therapy with defibrillator; HF, heart failure; HR, hazard ratio; ICD, implantable cardioverter‐defibrillator; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; MADIT‐CRT, Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy; MIRACLE, Multicenter InSync Randomized Clinical Evaluation; NYHA, New York Heart Association; OMT, optimal medical therapy; QRSd, QRS duration; RAFT, Resynchronization for Ambulatory Heart Failure; REVERSE, Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction.

Reproduced with permission and modified from Tompkins et al.34